Inventor · disambiguated record
Brian D. Livingston
Also filed as: LIVINGSTON BRIAN · LIVINGSTON BRIAN D
11 granted patents·14 pending applications·563 citations·filing 1993–2020
93Inventor score
Top patents by PatentIndex Score
25 records- 0194US6534482B1Expression vectors for stimulating an immune response and methods of using the sameEPIMMUNE INC·Filed 1999·Granted Mar 18, 2003·155 cites·4 claims
- 0292US7888472B2Optimized multi-epitope constructs and uses thereofEPIMMUNE INC·Filed 2009·Granted Feb 15, 2011·12 cites·6 claims
- 0390US7462354B2Method and system for optimizing minigenes and peptides encoded therebyPHARMEXA INC·Filed 2001·Granted Dec 9, 2008·31 cites·20 claims
- 0490US5750395ADNA encoding MAGE-1 C-terminal cytotoxic t lymphocyte immunogenic peptidesCYTEL CORP·Filed 1995·Granted May 12, 1998·73 cites·3 claims
- 0587US5858751ACompositions and methods for producing sialyltransferasesUNIV CALIFORNIA·Filed 1994·Granted Jan 12, 1999·99 cites·8 claims
- 0684US6689363B1Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositionsEPIMMUNE INC·Filed 1999·Granted Feb 10, 2004·69 cites·55 claims
- 0781US5962294ACompositions and methods for the identification and synthesis of sialyltransferasesUNIV CALIFORNIA·Filed 1993·Granted Oct 5, 1999·86 cites·4 claims
- 0878US7507803B2Optimized multi-epitope constructs and uses thereofGENIMMUNE N V·Filed 2003·Granted Mar 24, 2009·7 cites·4 claims
- 0976US6464980B1MAGE-1 c-terminal immunogenic peptidesEPIMMUNE INC·Filed 1996·Granted Oct 15, 2002·23 cites·5 claims
- 1072US7611713B2Inducing cellular immune responses to hepatitis B virus using peptide compositionsPHARMEXA INC·Filed 2003·Granted Nov 3, 2009·5 cites·5 claims
- 1160US2010049491A1Method and System for Optimizing Minigenes and Peptides Encoded TherebySETTE ALESSANDRO·Filed 2008·Application pending·0 cites
- 1260US2003216343A1Expression vectors for stimulating an immune response and methods of using the sameFiled 2003·Application pending·0 cites
- 1359US2010068228A1Inducing Cellular Immune Responses to Hepatitis B Virus Using Peptide and Nucleic Acid CompositionsPHARMEXA INC·Filed 2009·Application pending·0 cites
- 1453US2020289629A1Toxoplasma gondii vaccines and their useMCLEOD RIMA·Filed 2020·Application pending·0 cites
- 1553US2009196915A1Composition and methods of making and using influenza proteinsVAN NEST GARY·Filed 2008·Application pending·0 cites
- 1650US2013089596A1Compositions and methods of making and using influenza proteinsVAN NEST GARY·Filed 2012·Application pending·0 cites
- 1750US2007054262A1Methods of identifying optimal variants of peptide epitopesBAKER DENISE M·Filed 2004·Application pending·0 cites
- 1849US2005271676A1Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositionsEPIMMUNE INC·Filed 2005·Application pending·0 cites
- 1948US2011097352A9Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositionsPHARMEXA INC·Filed 2007·Application pending·0 cites
- 2048US2016193316A1Inducing Cellular Immune Responses to Plasmodium Falciparum Using Peptide and Nucleic Acid CompositionsEPIMMUNE INC·Filed 2015·Application pending·0 cites
- 2146US2009304746A1Inducing cellar immune responses to hepatitis C virus using peptide and nucleic acid compositionsPHARMEXA INC·Filed 2007·Application pending·0 cites
- 2246US2004248113A1Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded therebyFiled 2002·Application pending·0 cites
- 2344US2007059799A1Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositionsPHARMEXA INC·Filed 2006·Application pending·0 cites
- 2441US2019282679A1Toxoplasma gondii vaccines and their useMCLEOD RIMA·Filed 2017·Application pending·0 cites
- 2536US9266930B1Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositionsSETTE ALESSANDRO·Filed 1999·Granted Feb 23, 2016·3 cites·4 claims
Join the waitlist — get patent alerts
Get an alert when Brian D. Livingston files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →